Constellation Healthcare executives face criminal charges over $300M investment fraud scheme

The word fraud framed by other words
The DOJ has charged three executives at Constellation Healthcare Technologies for bilking investors out of hundreds of millions of dollars. (Getty/Devonyu)

The former executives of a now-defunct health technology company are facing criminal charges for what prosecutors are calling an “elaborate” fraud scheme that bilked investors out of more than $300 million.

In the criminal complaint filed Wednesday by the U.S. Attorney's Office in New Jersey, former CEO of Constellation Healthcare Technologies Inc. Parmijit “Paul” Parmar was charged with orchestrating a scheme to defraud an investment firm in a go-private transaction. He was charged alongside former Chief Financial Officer Sotirios “Sam” Zaharis and Executive Director Ravi Chivukul.

Constellation Healthcare, which filed for bankruptcy in March, is not named in the criminal complaint, but a parallel complaint (PDF) filed by the Securities and Exchange Commission (SEC) on Wednesday said Constellation and its executives falsified finical information in order to drive up the company’s value.

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

Federal prosecutors also filed a civil complaint (PDF) to seize four properties owned by Parmar.

Based in Houston, Texas, Constellation Healthcare at one time provided revenue cycle management technology, integrating data from EHRs to streamline claims processing.

RELATED: Investors say DOJ is investigating Outcome Health for fraud

Federal prosecutors alleged that the executives created fictitious companies that Constellation allegedly acquired, and then falsified bank records for those companies along with fake customer accounts to make it appear the company brought in more revenue than it did. As part of the go-private transition, one private investment firm based in New York sunk $82 million into the company and a consortium of financial lenders added $130 million in loans.  

The company was eventually valued at nearly $309.4 million when the transaction was finalized on January 20, 2017. Nine months later, the scheme was discovered and the executives resigned, prompting the company to file for bankruptcy.  

Suggested Articles

Humana and Microsoft announced a seven-year strategic partnership to build predictive solutions and intelligent automation to support Humana members.

Humana filed suit Friday against more than a dozen generic drugmakers alleging the companies engaged in price fixing.

Ochsner Health System is partnering with Color to launch a population health pilot program to integrate genetic information into preventive care.